Harolds J A
Integris Baptist Medical Center, Oklahoma City 73112-4481, USA.
J Okla State Med Assoc. 1999 Sep;92(9):457-61.
This article describes the use of 18-fluorodeoxyglucose (FDG) scans for the diagnostic evaluation of cancer patients. Since FDG is a positron emitting radio-pharmaceutical, a dedicated Positron Emission Tomography unit (PET) or a hybrid PET/SPECT (single photon emission computed tomography) unit is required for oncologic studies. As PET and PET/SPECT scanners become available to perform these images, it is important that knowledge regarding the usefulness of these images, and their limitations, be disseminated to health care providers. There are evolving uses of FDG scans; current use includes staging patients with non-small cell carcinoma of the lung, malignant melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, colorectal carcinoma, and head and neck carcinoma.
本文描述了18-氟脱氧葡萄糖（FDG）扫描在癌症患者诊断评估中的应用。由于FDG是一种发射正电子的放射性药物，肿瘤学研究需要使用专用的正电子发射断层扫描设备（PET）或PET/单光子发射计算机断层扫描（SPECT）混合型设备。随着PET和PET/SPECT扫描仪可用于获取这些图像，向医疗保健提供者传播有关这些图像的用途及其局限性的知识非常重要。FDG扫描的应用不断发展；目前的应用包括对非小细胞肺癌、恶性黑色素瘤、霍奇金病、非霍奇金淋巴瘤、结直肠癌以及头颈癌患者进行分期。
